GO:2001033 negative regulation of double-strand break repair via nonhomologous end joining: DNA Repair Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2001033 describes any process that stops, prevents, or reduces the frequency, rate, or extent of double-strand break repair via nonhomologous end joining (NHEJ).
• NHEJ is a major DNA double-strand break repair pathway that ligates broken DNA ends without a homologous template, and its negative regulation is critical for preventing mutagenic repair.
• Key negative regulators include TIRR (also known as NUDT16L1), which promotes nuclear export and degradation of the 53BP1-binding protein TIRR, thereby shifting repair toward homologous recombination.
• UBE2D3 and RNF168 orchestrate ATM signaling and NHEJ, and their dysregulation can alter pathway choice.
• TGFβ signaling and NRF2 activity modulate DNA repair, including NHEJ, and represent indirect regulatory layers.
• Dysregulation of NHEJ negative regulation is implicated in cancer, including breast cancer with Rb1 deficiency, and in HPV-associated tumors.
Description
Double-strand breaks (DSBs) are among the most cytotoxic DNA lesions, and cells repair them primarily through homologous recombination (HR) or nonhomologous end joining (NHEJ). NHEJ is active throughout the cell cycle and directly ligates broken ends, but it is error-prone and can drive genomic instability if unchecked. The Gene Ontology term GO:2001033, negative regulation of double-strand break repair via nonhomologous end joining, captures the biological processes that restrain NHEJ activity. Understanding this term is essential for researchers studying DNA repair pathway choice, because tipping the balance away from NHEJ toward HR or other pathways can influence sensitivity to DNA-damaging agents and PARP inhibitors. Recent studies have identified specific proteins that negatively regulate NHEJ, such as TIRR, whose nuclear export and degradation are mediated by DTX3L and regulate DNA repair pathway choice. Additionally, UBE2D3 facilitates NHEJ by orchestrating ATM signaling through control of RNF168, highlighting the complex regulation of this pathway. This article synthesizes authoritative GO data and verified PubMed literature to provide a research-grade overview of GO:2001033, its mechanisms, key genes, disease relevance, and experimental models.
negative regulation of double-strand break repair via nonhomologous end joining At A Glance
| GO ID | GO:2001033 |
|---|---|
| GO term | negative regulation of double-strand break repair via nonhomologous end joining |
| Ontology | biological_process |
| Synonym | negative regulation of NHEJ |
| Major function | Inhibits or reduces the frequency, rate, or extent of NHEJ-mediated DSB repair |
| Related pathway | DNA repair pathway choice, ATM signaling, TGFβ signaling |
| Key regulators | TIRR, DTX3L, UBE2D3, RNF168, 53BP1 |
| Disease relevance | Cancer, genomic instability, PARP inhibitor sensitivity |
What Is GO:2001033?
GO:2001033 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of double-strand break repair via nonhomologous end joining. In other words, it encompasses molecular events that inhibit the NHEJ machinery, either directly or indirectly, thereby influencing how cells repair DSBs.
Why Is negative regulation of double-strand break repair via nonhomologous end joining Important in Cell Biology?
Negative regulation of NHEJ is critical for maintaining genomic integrity because unrestrained NHEJ can lead to chromosomal translocations, deletions, and other mutagenic events. This process also determines cellular sensitivity to DNA-damaging therapies, as shifting repair toward or away from NHEJ affects the efficacy of PARP inhibitors and radiotherapy. Moreover, pathogens such as HPV can modulate DNA repair pathways, and understanding negative regulation of NHEJ may reveal therapeutic vulnerabilities in HPV-associated tumors.
• Prevents mutagenic NHEJ and maintains genome stability.
• Influences DNA repair pathway choice between NHEJ and HR.
• Modulates sensitivity to PARP inhibitors and other DNA-damaging agents.
• Implicated in cancer development, including breast cancer with Rb1 deficiency.
• Relevant to HPV-associated tumors where DNA repair is dysregulated.
• TGFβ signaling can regulate DNA repair, including NHEJ, linking microenvironment to repair.
• NRF2 activity affects DNA damage repair, including NHEJ.
• Provides potential targets for synthetic lethality strategies.
• Key for understanding resistance to radiotherapy and chemotherapy.
• Offers insights into aging and degenerative diseases linked to DNA repair defects.
What Happens During negative regulation of double-strand break repair via nonhomologous end joining?
Recognition of DSBs and initiation of NHEJ
In simple terms: When DNA breaks, cells quickly detect it and start the NHEJ repair process.
Upon DSB formation, the MRN complex and ATM are activated, leading to recruitment of 53BP1 and other factors that promote NHEJ. This initial step is subject to negative regulation by proteins that limit 53BP1 accumulation at break sites.
Negative regulation by TIRR and DTX3L
In simple terms: TIRR is a protein that normally blocks NHEJ, and DTX3L controls TIRR levels to allow repair to proceed.
TIRR (NUDT16L1) binds 53BP1 and inhibits its function, thereby negatively regulating NHEJ. DTX3L mediates TIRR nuclear export and degradation, which relieves inhibition and promotes NHEJ. This regulatory axis controls DNA repair pathway choice and influences PARP inhibitor sensitivity.
UBE2D3 and RNF168 in ATM signaling
In simple terms: UBE2D3 helps turn on ATM signaling, which can promote NHEJ, but its multi-level control of RNF168 also modulates the pathway.
UBE2D3 facilitates NHEJ by orchestrating ATM signaling through multi-level control of RNF168. This includes regulation of RNF168 ubiquitination and localization, which affects 53BP1 recruitment and NHEJ efficiency. Thus, UBE2D3 acts as a positive regulator of NHEJ, and its negative regulation would reduce NHEJ activity.
TGFβ and NRF2 as indirect regulators
In simple terms: Signals from the environment, like TGFβ, and stress responses like NRF2, can influence how DNA is repaired.
TGFβ signaling regulates DNA repair, including NHEJ, in a context-dependent manner. NRF2, a transcription factor involved in oxidative stress response, also plays roles in DNA damage repair, including NHEJ. These pathways can indirectly negatively regulate NHEJ by altering the expression or activity of core repair factors.
Consequences for pathway choice and genome stability
In simple terms: When NHEJ is blocked, cells may use other repair pathways, which can be good or bad depending on the situation.
Negative regulation of NHEJ promotes alternative repair pathways such as homologous recombination, which is generally error-free. However, excessive inhibition of NHEJ can lead to unrepaired breaks or use of error-prone alternative end joining, causing genomic instability. Therefore, tight regulation of NHEJ is essential for maintaining genome integrity.
Key Genes Involved in GO:2001033 negative regulation of double-strand break repair via nonhomologous end joining
The following genes and proteins are key players in the negative regulation of NHEJ, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TIRR (NUDT16L1) | Binds 53BP1 and inhibits NHEJ; negatively regulates NHEJ | Regulated by DTX3L; affects PARP inhibitor sensitivity |
| DTX3L | Mediates TIRR nuclear export and degradation | Controls DNA repair pathway choice |
| UBE2D3 | Facilitates NHEJ by orchestrating ATM signaling via RNF168 | Positive regulator of NHEJ; its inhibition reduces NHEJ |
| RNF168 | Ubiquitin ligase recruited to DSBs; promotes 53BP1 binding | Controlled by UBE2D3; affects NHEJ efficiency |
| 53BP1 | Promotes NHEJ by blocking end resection | Inhibited by TIRR; key factor in pathway choice |
| ATM | Kinase activated by DSBs; promotes NHEJ | Signaling hub; regulated by UBE2D3 |
| NRF2 | Transcription factor; roles in DNA damage repair | Modulates NHEJ indirectly |
| TGFβ | Cytokine; regulates DNA repair including NHEJ | Context-dependent effects on NHEJ |
| Rb1 | Tumor suppressor; deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition | Links cell cycle and DNA repair |
| ATR | Kinase involved in DNA damage response | Synthetic lethal with Rb1 deficiency |
| PKMYT1 | Kinase regulating cell cycle | Synthetic lethal with Rb1 deficiency |
| MRN complex | Initiates DSB recognition and resection | Upstream of NHEJ and HR |
| DNA-PKcs | Core NHEJ kinase | Essential for NHEJ; negatively regulated indirectly |
| XRCC4 | Ligase complex component | Required for NHEJ ligation |
| LIG4 | DNA ligase IV | Catalyzes ligation in NHEJ |
| Ku70/Ku80 | DSB end-binding heterodimer | Initiates NHEJ; target of regulation |
How Is negative regulation of double-strand break repair via nonhomologous end joining Regulated?
Negative regulation of NHEJ is controlled at multiple levels. DTX3L-mediated TIRR degradation relieves inhibition of NHEJ, effectively acting as a double-negative regulatory loop. UBE2D3 controls RNF168 and ATM signaling to facilitate NHEJ, so its downregulation or inhibition would negatively regulate NHEJ. TGFβ signaling can either promote or inhibit NHEJ depending on cellular context. NRF2 activity also modulates DNA repair, including NHEJ, through transcriptional regulation of repair genes. Additionally, cell cycle regulators such as Rb1 influence DNA repair pathway choice and synthetic lethal interactions with ATR and PKMYT1.
negative regulation of double-strand break repair via nonhomologous end joining and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TIRR (NUDT16L1) | Cancer, PARP inhibitor sensitivity | Knockout or overexpression in cancer cell lines |
| DTX3L | Cancer, DNA repair pathway choice | Knockout in HeLa or breast cancer cells |
| Rb1 | Breast cancer, synthetic lethality | Patient-derived xenografts with Rb1 deficiency |
| UBE2D3 | Cancer, NHEJ efficiency | Knockdown or knockout in U2OS cells |
| NRF2 | Cancer, oxidative stress response | Knockout in A549 or other cancer cells |
Cancer and genomic instability
Dysregulation of NHEJ negative regulation can lead to genomic instability and cancer. For example, TIRR and DTX3L control DNA repair pathway choice and affect PARP inhibitor sensitivity in cancer cells. Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer, linking cell cycle and DNA repair to therapeutic strategies. HPV-associated tumors often exhibit altered DNA repair signatures, including NHEJ components.
Therapeutic implications
Targeting negative regulators of NHEJ can sensitize tumors to DNA-damaging therapies. Inhibition of DTX3L or TIRR may shift repair toward HR, creating vulnerabilities in HR-deficient cancers. Synthetic lethal approaches with ATR and PKMYT1 inhibitors in Rb1-deficient breast cancer highlight the importance of pathway choice.
Other diseases
Defects in DNA repair, including NHEJ regulation, are associated with aging and neurodegenerative diseases, though specific links to GO:2001033 require further study. TGFβ and NRF2 pathways, which modulate NHEJ, are also implicated in fibrosis and inflammatory diseases.
From negative regulation of double-strand break repair via nonhomologous end joining-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does TIRR negatively regulate NHEJ? | TIRR knockout and overexpression cell lines |
| How does DTX3L affect TIRR stability? | DTX3L knockout with TIRR degradation assays |
| Does UBE2D3 control NHEJ via RNF168? | UBE2D3 knockdown and RNF168 mutants |
| What is the role of Rb1 in DNA repair pathway choice? | Rb1-deficient breast cancer cells and PDX |
| How does TGFβ regulate NHEJ? | TGFβ treatment in epithelial cells with NHEJ reporters |
| Does NRF2 modulate NHEJ? | NRF2 knockout or overexpression |
How to Study the negative regulation of double-strand break repair via nonhomologous end joining Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout screen | Gene essentiality and repair efficiency | Identify negative regulators of NHEJ |
| NHEJ reporter (EJ5-GFP) | NHEJ repair frequency | Test candidate regulators |
| Co-immunoprecipitation | Protein-protein interactions | Study TIRR-53BP1 interaction |
| Immunofluorescence | Repair foci formation | Assess 53BP1 recruitment |
| Western blot | Protein expression and degradation | Measure TIRR stability |
| RNA-seq | Transcriptional changes | Analyze TGFβ/NRF2 target genes |
| Comet assay | DNA damage levels | Evaluate repair capacity |
CRISPR knockout screens
Genome-wide CRISPR knockout screens can identify negative regulators of NHEJ by selecting for cells with altered sensitivity to DNA-damaging agents or by using NHEJ reporters.
Reporter assays for NHEJ
NHEJ reporter assays, such as the EJ5-GFP system, measure repair efficiency and can be used to test the impact of candidate negative regulators.
Proteomics and interactomics
Affinity purification mass spectrometry can identify proteins interacting with TIRR, 53BP1, or other NHEJ factors to uncover regulatory complexes.
Imaging of repair foci
Immunofluorescence for 53BP1, γH2AX, and other foci markers visualizes NHEJ activity and its regulation at the single-cell level.
How CRISPR Can Be Used to Study GO:2001033 negative regulation of double-strand break repair via nonhomologous end joining
Knockout
CRISPR knockout of negative regulators such as TIRR or DTX3L can increase NHEJ activity, while knockout of positive regulators like UBE2D3 decreases NHEJ. These models help dissect pathway choice.
Point Mutation
Point mutations in TIRR or RNF168 can disrupt specific interactions or catalytic activities, allowing precise mapping of regulatory domains.
Knock-in
Knock-in of tagged versions of TIRR or 53BP1 enables live-cell imaging and proteomic analysis of NHEJ regulation.
Overexpression
Overexpression of TIRR or other negative regulators can suppress NHEJ and sensitize cells to PARP inhibitors, providing models for therapeutic studies.
How EDITGENE Supports negative regulation of double-strand break repair via nonhomologous end joining Research
Researchers studying negative regulation of double-strand break repair via nonhomologous end joining-related genes often need to determine whether a candidate gene is causally involved in NHEJ regulation or is merely correlated with repair phenotypes. EDITGENE provides comprehensive CRISPR-based services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of double-strand break repair via nonhomologous end joining research.
Frequently Asked Questions About negative regulation of double-strand break repair via nonhomologous end joining
What is GO:2001033?
GO:2001033 is a Gene Ontology term for any process that stops, prevents, or reduces the frequency, rate, or extent of double-strand break repair via nonhomologous end joining.
What genes are involved in negative regulation of NHEJ?
Key genes include TIRR (NUDT16L1), DTX3L, UBE2D3, RNF168, and 53BP1, among others.
How does TIRR regulate NHEJ?
TIRR binds 53BP1 and inhibits NHEJ; its nuclear export and degradation by DTX3L relieves this inhibition.
What is the role of UBE2D3 in NHEJ?
UBE2D3 facilitates NHEJ by orchestrating ATM signaling through multi-level control of RNF168.
Why is negative regulation of NHEJ important in cancer?
Dysregulation can lead to genomic instability and affect sensitivity to PARP inhibitors and other therapies.
How can I study negative regulation of NHEJ?
Use CRISPR knockout screens, NHEJ reporter assays, and imaging of repair foci.
What diseases are linked to NHEJ dysregulation?
Cancer, including breast cancer and HPV-associated tumors, as well as potential roles in aging and neurodegeneration.
What are the synonyms for GO:2001033?
The synonym is negative regulation of NHEJ.
Which proteins are targeted by DTX3L?
DTX3L mediates TIRR nuclear export and degradation.
How does TGFβ affect NHEJ?
TGFβ signaling regulates DNA repair, including NHEJ, in a context-dependent manner.
Conclusion
GO:2001033, negative regulation of double-strand break repair via nonhomologous end joining, is a critical biological process that ensures genome stability by restraining error-prone NHEJ. Key regulators such as TIRR, DTX3L, and UBE2D3 modulate this pathway, with implications for cancer therapy and DNA repair research. Understanding these mechanisms can guide the development of targeted treatments and synthetic lethal strategies. EDITGENE offers comprehensive CRISPR services to facilitate functional studies of these regulators.
References
- 2. Ye Q et al.. 2024. DTX3L-mediated TIRR nuclear export and degradation regulates DNA repair pathway choice and PARP inhibitor sensitivity.. Nat Commun 15(1):10596 PMID: 39632881
- 3. Hussain SS et al.. 2021. Genomic Signatures in HPV-Associated Tumors.. Viruses 13(10) PMID: 34696429
- 4. Jiang XT et al.. 2025. Rb1 deficiency induces synthetic lethality with ATR and PKMYT1 coinhibition in breast cancer cell lines and patient-derived xenografts.. Sci Transl Med 17(830):eadx6797 PMID: 41442499
- 5. Yalçin Z et al.. 2024. UBE2D3 facilitates NHEJ by orchestrating ATM signalling through multi-level control of RNF168.. Nat Commun 15(1):5032 PMID: 38866770
- 6. Symington LS. 2014. End resection at double-strand breaks: mechanism and regulation.. Cold Spring Harb Perspect Biol 6(8) PMID: 25085909
- 7. Li J et al.. 2023. Roles of NRF2 in DNA damage repair.. Cell Oncol (Dordr) 46(6):1577-1593 PMID: 37365451
- 8. Liu Q et al.. 2019. Misrepair in Context: TGFβ Regulation of DNA Repair.. Front Oncol 9:799 PMID: 31552165
